The DOI matches its Crossref record.
Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study
Abstract
Background Tuberculosis (TB) remains a global health problem. The application of rifampicin-based regimens for antimycobacterial therapy is hampered by its marked hepatotoxicity which results in poor adherence and may contribute to prolonged therapy or treatment failure. The purpose of this prospective investigation was to evaluate the hepatoprotective effectiveness of oral ursodeoxycholic acid (UDCA) (250-500 mg TID) administered to TB- or non-TB mycobacterial (NTM)-infected patients with drug-induced hepatotoxicity and ongoing therapy. Methods Study population: During 2009-2017, 27 patients (11 women, 16 men, aged 19-90 years; median age 44 years, 16 Caucasians, 10 Africans, 1 Asian) out of 285 patients with active TB (24/261) or NTM infections (3/24) treated at our TB Center developed clinically relevant hepatotoxicity. Oral UDCA was administered to treat hepatotoxicity. Results Twenty-one out of 27 patients (77.8%) showed normalization of elevated enzymes (alanine transferase and aspartate aminotransferase), alkaline phosphatase, and bilirubin while continuing TB treatment and 5 patients demonstrated a significant reduction of liver enzymes (18.5%). No change was observed in 1 patient (3.7%). Drug dose was not reduced in all patients; they all showed radiological and clinical improvement. There were no significant side effects. Conclusion Oral administration of UDCA to TB patients developing anti-TB drug-induced liver injury may reverse hepatotoxicity in adults.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Ursodeoxycholic acid may improve pruritus and DILI recovery, but large randomized controlled trials are lacking for the optimal dose and duration.[21]”
From Drug-induced liver injury: Diagnosis, management and the role of liver transplantation (2025) · cites this paper as [21]
In the citing paper
“Ursodeoxycholic acid (UDCA) may improve symptoms of pruritus and hasten DILI recovery, but large, randomized controlled trials are needed to determine the optimal dose and duration.”
From Drug-induced liver injury. Part I: Classification, diagnosis and treatment (2025) · cites this paper as [48]
In the citing paper
“Ursodeoxycholic acid may improve symptoms of pruritus and hasten DILI recovery, but large, randomized controlled trials are needed to determine the optimal dose and duration.155”
From AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury (2023) · cites this paper as [155]
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 19
- Schaberg, 2017, Tuberculosis guideline for adults – Guideline for diagnosis and treatment of tuberculosis including LTBI testing and treatment of the German Central Committee (DZK) and the German Respiratory Society (DGP), Pneumologie, 325
- Abbara, 2017, Drug-induced liver injury from antituberculous treatment: A retrospective study from a large TB centre in the UK, BMC Infect Dis, 231
- Chen, 2015, Key factors of susceptibility to anti-tuberculosis drug-induced hepatotoxicity, Arch Toxicol, 883
- Yew WW, Chang KC, Chan DP. Oxidative stress and first-line antituberculosis drug-induced hepatotoxicity. Antimicrob Agents Chemother 2018;62. pii: e02637-17. · DOI
- Ramappa, 2013, Hepatotoxicity related to anti-tuberculosis drugs: Mechanisms and management, J Clin Exp Hepatol, 37
- Saukkonen, 2006, An official ATS statement: Hepatotoxicity of antituberculosis therapy, Am J Respir Crit Care Med, 935
- Kishore, 2007, Drug induced hepatitis with anti-tubercular chemotherapy: Challenges and difficulties in treatment, Kathmandu Univ Med J (KUMJ), 256
- Asgarshirazi, 2015, Ursodeoxycholic acid can improve liver transaminase quantities in children with anticonvulsant drugs hepatotoxicity: A pilot study, Acta Med Iran, 351
- Cheng, 2017, Ursodeoxycholic acid for cystic fibrosis-related liver disease, Cochrane Database Syst Rev, CD000222
- Grand'Maison, 2014, The effects of ursodeoxycholic acid treatment for intrahepatic cholestasis of pregnancy on maternal and fetal outcomes: A meta-analysis including non-randomized studies, J Obstet Gynaecol Can, 632
- Reardon, 2016, Ursodeoxycholic acid in treatment of non-cholestatic liver diseases: A systematic review, J Clin Transl Hepatol, 192
- Saksena, 1997, Ursodeoxycholic acid in the treatment of liver diseases, Postgrad Med J, 75
- Wree, 2011, Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury, Digestion, 54
- Chen, 2011, The protective effects of ursodeoxycholic acid on isoniazid plus rifampicin induced liver injury in mice, Eur J Pharmacol, 53
- Alpana M, Daga MK, Aggarwal S, Nidhi A. Treatment for tuberculosis in a patient with Dubin-Johnson syndrome. BMJ Case Rep 2015;2015. pii: bcr2015211123. · doi:10.1136/bcr-2015-211123
- Saito, 2016, Effectiveness of hepatoprotective drugs for anti-tuberculosis drug-induced hepatotoxicity: A retrospective analysis, BMC Infect Dis, 668
- Borzakova, 2018, Principles of diagnosis and therapy of drug-induced liver injury in children with tuberculosis, Ross Vestn Perinatol Pediatr, 91
- Miyazawa, 2015, Isoniazid-induced acute liver failure during preventive therapy for latent tuberculosis infection, Intern Med, 591
- Marschall, 2012, Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans, Digestion, 244
Cited by
AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury
Fontana, R. J., Liou, I., Reuben, A., Suzuki, A., Fiel, M. I., Lee, W., & Navarro, V. (2023) · Hepatology · doi:10.1002/hep.32689 · Cited by 340
Drug induced liver injury: an update
Garcia-Cortes, M., Robles-Diaz, M., Stephens, C., Ortega-Alonso, A., Lucena, M. I., & Andrade, R. J. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02885-1 · Cited by 286
Drug-induced liver injury. Part I: Classification, diagnosis and treatment
Kozielewicz, D. M., Stalke, P., & Skrzypek, J. (2025) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2025.148329 · Cited by 19
Drug-induced liver injury: Diagnosis, management and the role of liver transplantation
Ozturk, N. B., Uskudar, E., Toruner, M. D., Simsek, C., & Gurakar, A. (2025) · Hepatology Forum · doi:10.14744/hf.2024.2024.0003 · Cited by 9
Metadata
- Authors
- Lang, S., Ortmann, J., Rostig, S., & Schiffl, H.
- Venue
- International Journal of Mycobacteriology
- Publisher
- Medknow
- Published
- 2019
- Volume
- 8
- Issue
- 1
- Pages
- 89
- ISSN
- 2212-5531
- Cited by
- 23
- References
- 0
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. https://app.cochat.ai/papers/10.4103/ijmy.ijmy_159_18
- The paper
- Lang, S., Ortmann, J., Rostig, S., & Schiffl, H. (2019). Ursodeoxycholic acid attenuates hepatotoxicity of multidrug treatment of mycobacterial infections: A prospective pilot study. International Journal of Mycobacteriology. https://doi.org/10.4103/ijmy.ijmy_159_18
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.